ESC 365 - Sacubitril/valsartan eligibility and outcomes in the ESC HFA EORP Heart Failure Long-Term Registry: bridging between the PARADIGM-HF trial, ESC Guidelines and real-world

HFA Premium Access

Sacubitril/valsartan eligibility and outcomes in the ESC HFA EORP Heart Failure Long-Term Registry: bridging between the PARADIGM-HF trial, ESC Guidelines and real-world

Session: Late breaking trial IV - Registries

Topic: Pharmacotherapy

Speaker: Doctor C. Kapelios (Athens, GR)

Event: Heart Failure 2019

Congress Presentation

Add to my library

About the speaker

Doctor Chris Kapelios

Onassis Cardiac Surgery Center, Athens (Greece)

3 presentations

0 follower

10 more presentations in this session

Prospective evaluation of natriuretic peptide based referral of chronic heart failure patients in primary care (PREFER): a pragmatic real world intervention study

Speaker: Professor F. Gustafsson (Copenhagen, DK)

Discussion - PREFER.

Discussion - PARADIGM-HF.

Clinical presentation, management and 6-month outcome of women diagnosed with PPCM from Europe, Africa, Asia Pacific and Middle East

Speaker: Professor K. Sliwa (Cape Town, ZA)

Discussion - Clinical presentation, management and 6-month outcome of women diagnosed with PPCM from Europe, Africa, Asia Pacific and Middle East.

Access the full session

Late breaking trial IV - Registries

Speakers: Doctor C. Kapelios, Professor F. Gustafsson, Professor K. Sliwa

About the event

Heart Failure 2019

25 May - 28 May 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources